Supplemental material
Report
Development of a quantitative relationship between CAR-affinity, antigen abundance, tumor cell depletion and CAR-T cell expansion using a multiscale systems PK-PD model
Aman P. Singha Discovery and Translational Research, Biologics Development Sciences, Janssen Biotherapeutics, Spring House, PA, USACorrespondence[email protected]
https://orcid.org/0000-0002-1886-2624View further author information
https://orcid.org/0000-0002-1886-2624View further author information, , , , , , & show allRelated Research Data
Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells
Source:
Mary Ann Liebert Inc
Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR.
Source:
Springer Science and Business Media LLC
Expanding the Therapeutic Window for CAR T Cell Therapy in Solid Tumors: The Knowns and Unknowns of CAR T Cell Biology.
Source:
Frontiers Media SA
Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia
Source:
American Association for Cancer Research (AACR)
CAR T Cells in Solid Tumors: Blueprints for Building Effective Therapies.
Source:
Frontiers Media SA
Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia.
Source:
American Society of Hematology
CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Source:
American Society for Clinical Investigation
T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
Source:
American Association for the Advancement of Science (AAAS)
Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human
Source:
Springer Science and Business Media LLC
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Source:
Massachusetts Medical Society
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Source:
Massachusetts Medical Society
Application of Pharmacokinetic-Pharmacodynamic Modeling and Simulation for Antibody-Drug Conjugate Development
Source:
Springer Science and Business Media LLC
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
Source:
MASSACHUSETTS MEDICAL SOC
FLAG-tagged CD19-specific CAR-T cells eliminate CD19-bearing solid tumor cells in vitro and in vivo.
Source:
IMR Press
CD8+ lymphocyte control of SIV infection during antiretroviral therapy
Source:
Public Library of Science (PLoS)
The development of CAR design for tumor CAR-T cell therapy.
Source:
Impact Journals, LLC
Linking provided by
